Table 1

Characteristics of retinopathy of prematurity patients receiving IVC

Patient	Sex	GA (weeks)	BW (g)	Zone, stage		PMA of IVC (weeks)	Follow-up time (weeks)
Patient	Sex	GA (weeks)	BW (g)	OD	OS	PMA of IVC (weeks)	Follow-up time (weeks)
1	M	30+5	1500	I, 1+	I, 1+	34+3	26
2	M	27+2	1000	II, 3+	II, 3+	33+6	40
3	M	27	1100	I 1+	I, 1+	30	30
4	F	28+3	1220	I, 3+	I, 3+	33+5	31
5	M	28	1370	II, 3+	II, 3+	35+4	36
6	F	27+2	1040	II, 3+	II, 3+	32+4	30
7	M	27+1	900	II, 3+	II, 3+	32	28
8	F	29+3	1200	II, 3+	II, 3+	33+2	42
9	M	28	1150	AP-ROP	AP-ROP	33+3	30
10	F	25+5	810	II,3+	II, 3+	30+6	38
11	M	28+2	1260	II, 2+	II, 2+	35	27
12	M	27	1000	II, 3+	II, 3+	34+6	30
13	M	28+6	1580	II, 2+	II, 2+	35+5	29
14	F	30+3	990	II, 2+	II, 2+	36+4	26
15	F	29+4	1200	II, 2+	II, 2+	36+2	27
16	F	31+5	1450	II, 3+	II, 3+	36+5	28
17	M	26+1	1000	II, 3+	I, 3+	33+1	32
18	F	29+2	1200	II, 3+	II, 3+	33+6	29
19	M	31	1470	I, 2+	I, 2+	35+3	28
20	M	29+3	1610	II, 2+	II, 2+	36+2	30
21	M	29	900	AP-ROP	AP-ROP	36+6	32
22	F	30	1350	II, 3+	II, 3+	37+2	28
23	M	25+6	540	II, 3+	II, 3+	31+5	40
24	M	28+1	1280	II, 3+	II, 3+	32+6	27

AP-ROP, aggressive posterior retinopathy of prematurity; BW, birth weight; F, female; GA, gestational age; IVC, intravitreal conbercept; M, male; PMA, postmenstrual age; ROP, retinopathy of prematurity.